Stockscreener 앱 받기
86.22
1.47%
1.175
전일 마감가:
$85.05
열려 있는:
$85.12
하루 거래량:
89,215
Relative Volume:
0.12
시가총액:
$7.05B
수익:
$39.21M
순이익/손실:
$-311.35M
주가수익비율:
-23.44
EPS:
-3.6793
순현금흐름:
$-234.34M
1주 성능:
+1.21%
1개월 성능:
+9.20%
6개월 성능:
+44.10%
1년 성능:
+257.80%
1일 변동 폭
$85.09
$88.65
1주일 범위
$82.28
$89.55
52주 변동 폭
$24.23
$103.00
Kymera Therapeutics Inc Stock (KYMR) Company Profile
명칭
Kymera Therapeutics Inc
전화
857-285-5314
주소
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
86.32 | 6.94B | 39.21M | -311.35M | -234.34M | -3.6793 |
VRTX
Vertex Pharmaceuticals Inc
|
436.95 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
742.31 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
795.16 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
325.77 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
306.58 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2026-01-06 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-11-03 | 재개 | Guggenheim | Buy |
| 2025-10-24 | 재확인 | B. Riley Securities | Buy |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-16 | 개시 | RBC Capital Mkts | Outperform |
| 2025-07-30 | 재개 | B. Riley Securities | Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-06-03 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-05-20 | 재개 | Stifel | Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Market Perform |
| 2024-12-02 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-26 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | 개시 | Oppenheimer | Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-01-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | 개시 | Truist | Buy |
| 2023-05-05 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | 개시 | Raymond James | Mkt Perform |
| 2022-08-15 | 개시 | Jefferies | Buy |
| 2022-08-03 | 개시 | Goldman | Buy |
| 2022-07-20 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-03-10 | 개시 | JP Morgan | Neutral |
| 2022-02-10 | 개시 | Wells Fargo | Overweight |
| 2021-09-30 | 개시 | B. Riley Securities | Neutral |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-09-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-14 | 개시 | Berenberg | Buy |
| 2020-12-04 | 개시 | H.C. Wainwright | Buy |
| 2020-09-15 | 개시 | BofA Securities | Neutral |
| 2020-09-15 | 개시 | Cowen | Outperform |
| 2020-09-15 | 개시 | Guggenheim | Buy |
| 2020-09-15 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Kymera Therapeutics Inc 주식(KYMR)의 최신 뉴스
Kymera Therapeutics (KYMR) Receives Fast Track Designation for K - GuruFocus
FDA grants fast track status to Kymera’s KT-621 for asthma By Investing.com - Investing.com South Africa
Kymera Therapeutics Advances KT-621 with FDA Fast Track Designation for Asthma and Atopic Dermatitis Trials - Quiver Quantitative
FDA Fast Track puts Kymera's once-daily oral asthma drug in focus - Stock Titan
Kymera Therapeutics (KYMR) to present Phase 1b BroADen trial data for KT-621 at AAD 2026 - MSN
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma - Bitget
KYMR SEC FilingsKymera Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Gilead expands Tempus AI partnership to boost oncology pipeline - MSN
Discipline and Rules-Based Execution in KYMR Response - Stock Traders Daily
Kymera Therapeutics CBO sells $500k in KYMR stock By Investing.com - Investing.com Australia
Kymera Therapeutics (NASDAQ:KYMR) Insider Noah Goodman Sells 8,264 Shares - MarketBeat
Noah Goodman Sells 2,000 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Kymera Therapeutics CBO sells $500k in KYMR stock - Investing.com
Kymera Therapeutics (KYMR) CBO trades shares under Rule 10b5-1 plan - Stock Titan
KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200 - TradingView — Track All Markets
Gilead Expands Tempus AI Partnership To Boost Oncology Pipeline - Sahm
Gilead exercises option to license Kymera’s KT-200 - BioWorld News
H.C. Wainwright reiterates Kymera Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Kymera Therapeutics Announces Gilead Sciences' Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate - Investing News Network
Kymera Therapeutics (NASDAQ: KYMR) brokered sale notice for 11,611 shares - Stock Titan
Gilead Sciences (GILD) Secures Exclusive Rights to KT-200 from K - GuruFocus
Gilead exercises option on Kymera’s CDK2 degrader for $45M By Investing.com - Investing.com India
Gilead exercises option on Kymera’s CDK2 degrader for $45M - Investing.com
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate - The Manila Times
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 ... - Bluefield Daily Telegraph
CEO Change: Is now the right time to enter Kymera Therapeutics IncEarnings Growth Summary & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Aug PostEarnings: What is the earnings history of Kymera Therapeutics Inc2026 Dividend Review & Advanced Technical Analysis Signals - baoquankhu1.vn
Kymera added to Citi catalyst watch list on atopic dermatitis asset data readout - MSN
SG Americas Securities LLC Grows Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics Soars After Multiple Analyst Upgrades; Retail Sentiment Turns Extremely Bullish - MSN
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up - AOL.com
Jeremy Chadwick Sells 7,600 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) COO Sells $1,251,134.40 in Stock - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Director Sells $631,738.00 in Stock - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Director Elena Ridloff Sells 4,600 Shares - MarketBeat
Kymera Therapeutics COO sells $1.9 million in shares By Investing.com - Investing.com Canada
Kymera Therapeutics (NASDAQ: KYMR) director sells 12,000 shares under 10b5-1 plan - Stock Titan
KYMR (NASDAQ) director/insider plans 4,600-share option exercise; prior 7,400-share 10b5-1 sale - Stock Titan
Form 144 and 10b5-1 sales reported for KYMR (NASDAQ: KYMR) - Stock Titan
Kymera's eczema drug gets fast track designation in the United States - MSN
Layoff Watch: What are Kymera Therapeutics Incs earnings expectationsBear Alert & Free Verified High Yield Trade Plans - baoquankhu1.vn
[144] Kymera Therapeutics, Inc. SEC Filing - Stock Titan
Behavioral Patterns of KYMR and Institutional Flows - Stock Traders Daily
Aug Volume: Is Kymera Therapeutics Inc forming a bullish divergence2026 Geopolitical Influence & Fast Moving Stock Watchlists - baoquankhu1.vn
Does Positive KT-621 Atopic Dermatitis Data Change The Bull Case For Kymera Therapeutics (KYMR)? - Yahoo Finance
Kymera Therapeutics Updates Bylaws on Federal Securities Litigation - TipRanks
Kymera Therapeutics Inc (KYMR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.62%
자본화:
|
볼륨(24시간):